**Haemophilus influenzae Type b**

*Haemophilus influenzae* is a cause of bacterial infections that are often severe, particularly among infants. It was first described by Pfeiffer in 1892. During an outbreak of influenza he found the bacteria in sputum of patients and proposed a causal association between this bacterium and the clinical syndrome known as influenza. The organism was given the name *Haemophilus* by Winslow, et al. in 1920. It was not until 1933 that Smith, et al. established that influenza was caused by a virus and that *H. influenzae* was a cause of secondary infection.

In the 1930s, Margaret Pittman demonstrated that *H. influenzae* could be isolated in encapsulated and unencapsulated forms. She identified six capsular types (a–f), and observed that virtually all isolates from cerebrospinal fluid (CSF) and blood were of the capsular type b.

Before the introduction of effective vaccines, *H. influenzae* type b (Hib) was the leading cause of bacterial meningitis and other invasive bacterial disease among children younger than 5 years of age; approximately one in 200 children in this age group developed invasive Hib disease. Nearly all Hib infections occurred among children younger than 5 years of age, and approximately two-thirds of all cases occurred among children younger than 18 months of age.

**Haemophilus influenzae**

*Haemophilus influenzae* is a gram-negative coccobacillus. It is generally aerobic but can grow as a facultative anaerobe. In vitro growth requires accessory growth factors, including “X” factor (hemin) and “V” factor (nicotinamide adenine dinucleotide [NAD]).

Chocolate agar media are used for isolation. *H. influenzae* will generally not grow on blood agar, which lacks NAD.

The outermost structure of *H. influenzae* is composed of polyriboyl-ribitol phosphate (PRP), a polysaccharide that is responsible for virulence and immunity. Six antigenically and biochemically distinct capsular polysaccharide serotypes have been described; these are designated types a through f. In the prevaccine era, type b organisms accounted for 95% of all strains that caused invasive disease.
Pathogenesis

The organism enters the body through the nasopharynx. Organisms colonize the nasopharynx and may remain only transiently or for several months in the absence of symptoms (“asymptomatic carrier”). In the prevaccine era, Hib could be isolated from the nasopharynx of 0.5%–3% of normal infants and children but was not common in adults. Nontypeable (unencapsulated) strains are also frequent inhabitants of the human respiratory tract.

In some persons, the organism causes an invasive infection. The exact mode of invasion to the bloodstream is unknown. Antecedent viral or mycoplasma infection of the upper respiratory tract may be a contributing factor. The bacteria spread in the bloodstream to distant sites in the body. Meninges are especially likely to be affected.

The most striking feature of Hib disease is age-dependent susceptibility. Hib disease is not common beyond 5 years of age. Passive protection of some infants is provided by transplacentally acquired maternal IgG antibodies and breastfeeding during the first 6 months of life. In the prevaccine era, peak attack rates occurred at 6–7 months of age, declining thereafter. The presumed reason for this age distribution is the acquisition of immunity to Hib with increasing age.

Antibodies to Hib capsular polysaccharide are protective. The precise level of antibody required for protection against invasive disease is not clearly established. However, a titer of 1 μg/mL 3 weeks postvaccination correlated with protection in studies following vaccination with unconjugated purified polyribosylribitol phosphate (PRP) vaccine and suggested long-term protection from invasive disease.

Acquisition of both anticapsular and serum bactericidal antibody is inversely related to the age-specific incidence of Hib disease.

In the prevaccine era, most children acquired immunity by 5–6 years of age through asymptomatic infection by Hib bacteria. Since only a relatively small proportion of children carry Hib at any time, it has been postulated that exposure to organisms that share common antigenic structures with the capsule of Hib (so-called “cross-reacting organisms”) may also stimulate the development of anticapsular antibodies against Hib. Natural exposure to Hib also induces antibodies to outer membrane proteins, lipopolysaccharides, and other antigens on the surface of the bacterium.

The genetic constitution of the host may also be important in susceptibility to infection with Hib. Risk for Hib disease has been associated with a number of genetic markers, but...
the mechanism of these associations is unknown. No single genetic relationship regulating susceptibility or immune responses to polysaccharide antigens has yet been convincingly demonstrated.

**Clinical Features**

Invasive disease caused by *H. influenzae* type b can affect many organ systems. The most common types of invasive disease are meningitis, epiglottitis, pneumonia, arthritis, and cellulitis.

**Meningitis** is infection of the membranes covering the brain and is the most common clinical manifestation of invasive Hib disease, accounting for 50%–65% of cases in the pre-vaccine era. Hallmarks of Hib meningitis are fever, decreased mental status, and stiff neck (these symptoms also occur with meningitis caused by other bacteria). Hearing impairment or other neurologic sequelae occur in 15%–30% of survivors. The case-fatality rate is 2%–5%, despite appropriate antimicrobial therapy.

**Epiglottitis** is an infection and swelling of the epiglottis, the tissue in the throat that covers and protects the larynx during swallowing. Epiglottitis may cause life-threatening airway obstruction.

**Septic arthritis** (joint infection), **cellulitis** (rapidly progressing skin infection which usually involves face, head, or neck), and **pneumonia** (which can be mild focal or severe empyema) are common manifestations of invasive disease.

**Osteomyelitis** (bone infection) and **pericarditis** (infection of the sac covering the heart) are less common forms of invasive disease. Otitis media and acute bronchitis due to *H. influenzae* are generally caused by nontypeable strains. Hib strains account for only 5%–10% of *H. influenzae* causing otitis media.

Nontypeable (unencapsulated) strains may cause invasive disease but are generally less virulent than encapsulated strains. Nontypeable strains are rare causes of serious infection among children but are a common cause of ear infections in children and bronchitis in adults.

**Laboratory Diagnosis**

A Gram stain of an infected body fluid may demonstrate small gram-negative coccobacilli suggestive of invasive *Haemophilus* disease. CSF, blood, pleural fluid, joint fluid, and middle ear aspirates should be cultured on appropriate media. A positive **culture** for *H. influenzae* establishes the diagnosis.
All isolates of *H. influenzae* should be serotyped. This is an extremely important laboratory procedure that should be performed on every isolate of *H. influenzae*, especially those obtained from children younger than 15 years of age. This test determines whether an isolate is type b, which is the only type that is potentially vaccine preventable. Serotyping is usually done by either the state health department laboratory or a reference laboratory.

**Antigen detection** may be used as an adjunct to culture, particularly in diagnosing *H. influenzae* infection in patients who have been partially treated with antimicrobial agents, in which case the organism may not be viable on culture. Two tests are available. *Latex agglutination* is a rapid, sensitive, and specific method to detect Hib capsular polysaccharide antigen in CSF, but a negative test does not exclude the diagnosis, and false-positive tests have been reported. Antigen testing of serum and urine is not recommended. *Counterimmunoelectrophoresis* is similar to latex agglutination but is less sensitive, takes longer, and is more difficult to perform.

**Medical Management**
Hospitalization is generally required for invasive Hib disease. Antimicrobial therapy with an effective third-generation cephalosporin (cefotaxime or ceftriaxone), or chloramphenicol in combination with ampicillin should be begun immediately. The treatment course is usually 10 days. Ampicillin-resistant strains of Hib are now common throughout the United States. Children with life-threatening illness in which Hib may be the etiologic agent should not receive ampicillin alone as initial empiric therapy.

**Epidemiology**

**Occurrence**
Hib disease occurs worldwide. However, the incidence outside the United States and Europe has not been determined.

**Reservoir**
Humans (asymptomatic carriers) are the only known reservoir. Hib does not survive in the environment on inanimate surfaces.

**Transmission**
The primary mode of Hib transmission is presumably by respiratory droplet spread, although firm evidence for this mechanism is lacking.
Temporal Pattern
Several studies in the prevaccine era described a bimodal seasonal pattern in the United States, with one peak during September through December and a second peak during March through May. The reason for this bimodal pattern is not known.

Communicability
The contagious potential of invasive Hib disease is considered to be limited. However, certain circumstances, particularly close contact with a case-patient (e.g., household, child care, or institutional setting) can lead to outbreaks or direct secondary transmission of the disease.

Secular Trends in the United States
H. influenzae infections became nationally reportable in 1991. Serotype-specific reporting continues to be incomplete.

Before the availability of national reporting data, several areas conducted active surveillance for H. influenzae disease, which allowed estimates of disease nationwide. In the early 1980s, it was estimated that about 20,000 cases occurred annually in the United States, primarily among children younger than 5 years of age (40–50 cases per 100,000 population). The incidence of invasive Hib disease began to decline dramatically in the late 1980s, coincident with licensure of conjugate Hib vaccines, and has declined by more than 99% compared with the prevaccine era.

From 1996 through 2000, an average of 1,247 invasive H. influenzae infections per year were reported to CDC in all age groups (range 1,162–1,398 per year). Of these, an average of 272 (approximately 22%) per year were among children younger than 5 years of age. Serotype was known for 76% of the invasive cases in this age group. Three-hundred forty-one (average of 68 cases per year) were due to type b.

There is evidence that Hib vaccines decrease the rate of carriage of Hib among vaccinated children, thereby decreasing the chance that unvaccinated children will be exposed.

Incidence is strikingly age-dependent. In the prevaccine era, up to 60% of invasive disease occurred before age 12 months, with a peak occurrence among children 6–11 months of age. Children 60 months of age and older account for less than 10% of invasive disease.

In 1998–2000, approximately 44% of children younger than 5 years of age with confirmed invasive Hib disease were younger than 6 months of age and too young to have
completed a three-dose primary vaccination series. Fifty-six percent were age 6 months or older and were eligible to have completed the primary vaccination series. Of these age-eligible children, 68% were either incompletely vaccinated (fewer than 3 doses) or their vaccination status was unknown. Thirty-two percent of children aged 6–59 months with confirmed type b disease had received three or more doses of Hib vaccine, including 22 who had received a booster dose 14 or more days before onset of their illness. The cause of Hib vaccine failure in these children is not known.

In 2004, among children younger than 5 years of age, 19 cases of invasive disease due to Hib were reported in the United States. In addition, another 177 cases caused by unknown H. influenzae serotypes were reported, so the actual number of Hib cases could be between 19 and 196. Most cases were among unvaccinated or incompletely vaccinated children.

**Risk factors** for Hib disease include exposure factors and host factors that increase the likelihood of exposure to Hib. Exposure factors include household crowding, large household size, child care attendance, low socioeconomic status, low parental education levels, and school-aged siblings. Host factors include race/ethnicity (elevated risk among African Americans, Hispanics, Native Americans—possibly confounded by socioeconomic variables that are associated with both race/ethnicity and Hib disease), chronic diseases (e.g., sickle cell anemia, antibody deficiency syndromes, malignancies, especially during chemotherapy), and possibly gender (risk is higher for males).

Protective factors (effect limited to infants younger than 6 months of age) include breastfeeding and passively acquired maternal antibody.

**Secondary Hib disease** is defined as illness occurring 1–60 days following contact with an ill child, and accounts for less than 5% of all invasive Hib disease. Among household contacts, six studies have found a secondary attack rate of 0.3% in the month following onset of the index case, which is about 600-fold higher than the risk for the general population. Attack rates varied substantially with age, from 3.7% among children 2 years of age and younger to 0% among contacts 6 years of age and older. In these household contacts, 64% of secondary cases occurred within the first week (excluding the first 24 hours) of disease onset in the index patient, 20% during the second week, and 16% during the third and fourth weeks.

Data are conflicting regarding the risk of secondary transmission among child care contacts. Secondary attack rates have varied from 0% to as high as 2.7%. Most studies seem to suggest that child care contacts are at relatively low risk for secondary transmission of Hib disease particularly if contacts are age-appropriately vaccinated.
**Haemophilus Influenza Type b**

**Haemophilus influenzae type b Vaccines**

**Characteristics**
A pure polysaccharide vaccine (HbPV) was licensed in the United States in 1985. The vaccine was not effective in children younger than 18 months of age. Estimates of efficacy in older children varied widely, from 88% to -69% (a negative efficacy implies greater disease risk for vaccinees than nonvaccinees). HbPV was used until 1988 but is no longer available in the United States.

The characteristics of the Hib polysaccharide were similar to other polysaccharide vaccines (e.g., pneumococcal, meningococcal). The response to the vaccine was typical of a T-independent antigen, most notably an age-dependent immune response, and poor immunogenicity in children 2 years of age and younger. In addition, no boost in antibody titer was observed with repeated doses, the antibody that was produced was relatively low-affinity IgM, and switching to IgG production was minimal.

**Haemophilus influenzae type b Polysaccharide-Protein Conjugate Vaccines**

Conjugation is the process of chemically bonding a polysaccharide (a somewhat ineffective antigen) to a protein “carrier,” which is a more effective antigen. This process changes the polysaccharide from a T-independent to a T-dependent antigen and greatly improves immunogenicity, particularly in young children. In addition, repeat doses of Hib conjugate vaccines elicit booster responses and allow maturation of class-specific immunity with predominance of IgG antibody. The Hib conjugates also cause carrier priming and elicit antibody to “useful” carrier protein.

The first Hib conjugate vaccine (PRP-D, ProHIBIT) was licensed in December 1987. This vaccine was not consistently immunogenic in children younger than 18 months of age. PRP-D is no longer available in the United States.

Three conjugate Hib vaccines are licensed for use in infants as young as 6 weeks of age (see below). All three vaccines utilize different carrier proteins. Two combination vaccines that contain Hib conjugate vaccine are also available.

<table>
<thead>
<tr>
<th>Vaccine</th>
<th>Protein Carrier</th>
<th>Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>HbOC (HibTITER)</td>
<td>Mutant diphtheria protein</td>
<td>Wyeth</td>
</tr>
<tr>
<td>PRP-T (ActHIB)</td>
<td>Tetanus toxoid</td>
<td>sanofi pasteur</td>
</tr>
<tr>
<td>PRP-OMP (PedvaxHIB)</td>
<td>Meningococcal group B outer membrane protein</td>
<td>Merck</td>
</tr>
</tbody>
</table>
Immunogenicity and Vaccine Efficacy

All three Hib conjugate vaccines licensed for use in infants are highly immunogenic. More than 95% of infants will develop protective antibody levels after a primary series of two or three doses. Clinical efficacy has been estimated at 95% to 100%. Invasive Hib disease in a completely vaccinated infant is uncommon.

Hib vaccine is immunogenic in patients with increased risk for invasive disease, such as those with sickle-cell disease, leukemia, or human immunodeficiency virus (HIV) infection, and those who have had a splenectomy. However, in persons with HIV infection, immunogenicity varies with stage of infection and degree of immunocompromise. Efficacy studies have not been performed in populations with increased risk of invasive disease.

Vaccination Schedule and Use

All infants, including those born prematurely, should receive a primary series of conjugate Hib vaccine (separate or in combination), beginning at 2 months of age. The number of doses in the primary series depends on the type of vaccine used. A primary series of PRP-OMP (PedvaxHIB) vaccine is two doses; HbOC (HibTITER) and PRP-T (ActHIB) require a three-dose primary series (see table below). A booster is recommended at 12–15 months regardless of which vaccine is used for the primary series.

<table>
<thead>
<tr>
<th>Vaccine</th>
<th>2 Months</th>
<th>4 Months</th>
<th>6 Months</th>
<th>12-15 Months</th>
</tr>
</thead>
<tbody>
<tr>
<td>HbOC</td>
<td>Dose 1</td>
<td>Dose 2</td>
<td>Dose 3</td>
<td>Booster</td>
</tr>
<tr>
<td>PRP-T</td>
<td>Dose 1</td>
<td>Dose 2</td>
<td>Dose 3</td>
<td>Booster</td>
</tr>
<tr>
<td>PRP-OMP</td>
<td>Dose 1</td>
<td>Dose 2</td>
<td></td>
<td>Booster</td>
</tr>
</tbody>
</table>

The recommended interval between primary series doses is 8 weeks, with a minimum interval of 4 weeks. At least 8 weeks should separate the booster dose from the previous (second or third) dose. Hib vaccines may be given simultaneously with all other vaccines.

Limited data suggest that Hib conjugate vaccines given before 6 weeks of age may induce immunologic tolerance to subsequent doses of Hib vaccine. A dose given before 6 weeks of age may reduce the response to subsequent doses. As a result, Hib vaccines, including combination vaccines that contain Hib conjugate, should never be given to a child younger than 6 weeks of age.
All three conjugate Hib vaccines licensed for use in infants are interchangeable. A series that includes vaccine of more than one type will induce a protective antibody level. If it is necessary to change vaccine type, three doses of any combination constitute the primary series. Any licensed conjugate vaccine may be used for the booster dose, regardless of what was administered in the primary series.

Unvaccinated children 7 months of age and older may not require a full series of three or four doses. The number of doses a child needs to complete the series depends on the child's current age.

### Detailed Vaccination Schedule for *Haemophilus influenzae* type b Conjugate Vaccines

<table>
<thead>
<tr>
<th>Vaccine</th>
<th>Age at 1st Dose (Months)</th>
<th>Primary Series</th>
<th>Booster</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>HbOC/PRP-T</strong></td>
<td>2-6</td>
<td>3 doses, 2 months apart</td>
<td>12-15 months*</td>
</tr>
<tr>
<td>(HibTITER, ActHIB)</td>
<td>7-11</td>
<td>2 doses, 2 months apart</td>
<td>12-15 months*</td>
</tr>
<tr>
<td></td>
<td>12-14</td>
<td>1 dose</td>
<td>2 months later</td>
</tr>
<tr>
<td></td>
<td>15-59</td>
<td>1 dose</td>
<td>—</td>
</tr>
<tr>
<td><strong>PRP-OMP</strong></td>
<td>2-6</td>
<td>2 doses, 2 months apart</td>
<td>12-15 months*</td>
</tr>
<tr>
<td>(PedvaxHIB)</td>
<td>7-11</td>
<td>2 doses, 2 months apart</td>
<td>12-15 months*</td>
</tr>
<tr>
<td></td>
<td>12-14</td>
<td>1 dose</td>
<td>2 months later</td>
</tr>
<tr>
<td></td>
<td>15-59</td>
<td>1 dose</td>
<td>—</td>
</tr>
</tbody>
</table>

*At least 2 months after previous dose

**HbOC or PRP-T (HibTITER, ActHIB)**

Previously unvaccinated infants aged 2–6 months should receive three doses of vaccine administered 2 months apart, followed by a booster dose at age 12–15 months, administered at least 2 months after the last dose. Unvaccinated children aged 7–11 months should receive two doses of vaccine 2 months apart, followed by a booster dose at age 12–15 months, administered at least 2 months after the last dose. Unvaccinated children aged 12–14 months should receive two doses of vaccine, at least 2 months apart. Any previously unvaccinated child aged 15–59 months should receive a single dose of vaccine.
Unvaccinated children aged 2–11 months should receive two doses of vaccine 2 months apart, followed by a booster dose at 12–15 months of age, at least 2 months after the last dose. Unvaccinated children aged 12–14 months should receive two doses of vaccine 2 months apart. Any previously unvaccinated child 15–59 months of age should receive a single dose of vaccine.

Children with a lapsed Hib immunization series (i.e., children who have received one or more doses of Hib-containing vaccine but are not up-to-date for their age) may not need all the remaining doses of a three- or four-dose series. Vaccination of children with a lapsed schedule is addressed in the catch-up schedule, published annually with the childhood vaccination schedule.

Hib invasive disease does not always result in development of protective anti-PRP antibody levels. Children younger than 24 months of age who develop invasive Hib disease should be considered susceptible and should receive Hib vaccine. Vaccination of these children should start as soon as possible during the convalescent phase of the illness. The schedule should be completed as recommended for the child’s age.

Vaccination of Older Children and Adults
In general, Hib vaccination of children older than 59 months of age is not recommended. The majority of older children are immune to Hib, probably from asymptomatic infection as infants. However, some older children and adults are at increased risk for invasive Hib disease and may be vaccinated if they were not vaccinated in childhood. These include those with functional or anatomic asplenia (e.g., sickle cell disease, postsplenectomy), immunodeficiency (in particular, persons with IgG2 subclass deficiency), immunosuppression from cancer chemotherapy, infection with HIV, and receipt of a hematopoietic stem cell transplant (HSCT). Previously unvaccinated persons older than 59 months of age with one of these high-risk conditions should be given at least one pediatric dose of any Hib conjugate vaccine.

Combination Vaccines
Two combination vaccines that contain _H. influenzae type b_ are available in the United States—a DTaP–Hib combination (TriHIBit, sanofi pasteur), and a hepatitis B–Hib combination (Comvax, Merck). Combination vaccines containing whole-cell pertussis vaccine and Hib are no longer available in the United States.
TriHIBit

TriHIBit was approved for use in the United States in September 1996. The vaccines are packaged together in separate vials, and the DTaP component (Tripedia) is used to reconstitute the Hib component (ActHIB). No other brand of DTaP and Hib vaccine may be used to produce this combination (e.g., Infanrix must not be substituted for Tripedia). In addition, when supplied as TriHIBit, the DTaP and Hib components have a single lot number. Providers should generally use only the DTaP and Hib supplied together as TriHIBit. However, it is acceptable to combine Tripedia and ActHIB that have been supplied separately (i.e., not packaged as TriHIBit). In this situation, the lot numbers of both vaccines should be recorded.

Because of evidence of reduced immunogenicity of the Hib component when used as a combination, TriHIBit is not approved by the Food and Drug Administration for use as the primary series at 2, 4, or 6 months of age. It is approved only for the fourth dose of the DTaP and Hib series. If TriHIBit is administered as one or more doses of the primary series at 2, 4, or 6 months of age, the Hib doses should be disregarded, and the child should be revaccinated as age-appropriate for Hib. The DTaP doses may be counted as valid and do not need to be repeated.

Although TriHIBit cannot be used in the primary series at 2, 4, or 6 months of age, it may be used as the booster (final) dose following a series of single-antigen Hib vaccine or combination hepatitis B–Hib vaccine (Comvax). Therefore, TriHIBit can be used if the child is 12 months of age or older and has received at least one prior dose of Hib vaccine 2 or more months earlier and TriHIBit will be the last dose in the Hib series. For example, TriHIBit can be used for the booster dose at 12–15 months of age in a child who has received Comvax or PedvaxHib at 2 and 4 months of age, or three prior doses of HibTiter or ActHib. TriHIBit can also be used at 15–59 months of age in a child who has received at least one prior dose of any Hib-containing vaccine. TriHIBit should not be used if the child has received no prior Hib doses.

Comvax

Comvax is a combination hepatitis B–Hib vaccine, licensed in October 1996. The vaccine contains a standard dose of PRP-OMP (PedvaxHIB), and 5 mcg (pediatric dose) of Merck’s hepatitis B vaccine. Comvax is licensed for use when either or both antigens are indicated. However, because of the potential of immune tolerance to the Hib antigen, Comvax should not be used in infants younger than 6 weeks of age (i.e., the birth dose of hepatitis B, or a dose at 1 month of age, if the infant is on a 0-1-6-month schedule).
**Haemophilus Influenza Type b**

Convax is not licensed for infants whose mothers are known to be hepatitis B surface antigen positive (i.e., acute or chronic infection with hepatitis B virus). However, the vaccine contains the same dose of Merck's hepatitis B vaccine recommended for these infants, so response to the hepatitis B component of Convax should be adequate. The Advisory Committee on Immunization Practices (ACIP) has approved off-label use of Convax in children whose mother is HBsAg positive or whose HBsAg status is unknown. See http://www.cdc.gov/nip/vfc/acip_recs/1003hepb.pdf.

Recommendations for spacing and timing of Convax are the same as those for the individual antigens. In particular, the third dose must be given at 12 months of age or older and at least 2 months after the second dose, as recommended for PRP-OMP.

**Adverse Reactions Following Vaccination**

Adverse reaction following Hib conjugate vaccines are not common. Swelling, redness, or pain have been reported in 5%–30% of recipients and usually resolve within 12–24 hours. Systemic reactions such as fever and irritability are infrequent. Serious adverse reactions are rare. Available information on adverse reactions suggests that the risks for local and systemic reactions following TriHIBit administration are similar to those following concurrent administration of its individual component vaccines, and are probably due to the DTaP vaccine.

All serious adverse events that occur after receipt of any vaccine should be reported to the Vaccine Adverse Events Reporting System (VAERS) (http://vaers.hhs.gov/).

**Contraindications and Precautions to Vaccination**

Vaccination with Hib conjugate vaccine is contraindicated for persons known to have experienced a severe allergic reaction (anaphylaxis) following a prior dose of that vaccine. Vaccination should be delayed for children with moderate or severe acute illnesses. Minor illnesses (e.g., mild upper respiratory infection) are not contraindications to vaccination. Hib conjugate vaccines are contraindicated for children younger than 6 weeks of age because of the potential for development of immunologic tolerance.

Contraindications and precautions for the use of TriHIBit and Convax are the same as those for its individual component vaccines (i.e., DTaP, Hib, and hepatitis B).
Vaccine Storage and Handling
All Hib conjugate vaccines should be shipped in insulated containers to prevent freezing. Unreconstituted or liquid vaccine should be stored at refrigerator temperature (35 –46°F [2 –8°C]). Hib vaccine must not be frozen.

ActHIB should be used within 24 hours of reconstitution and TriHIBit should be used immediately (within 30 minutes).

Surveillance and Reporting of Hib Disease
Invasive Hib disease is a reportable condition in most states. All healthcare workers should report any case of invasive Hib disease to local and state health departments.

Selected References


